Trader Lexicon - LXRX CFD
Ajouter aux favoris- Résumé
- Données historiques
- Événements
- Compte de résultat
- Bilan
- Flux de trésorerie
- Capital
Conditions de trading
| Écart | 0.05 | ||||||||
|
Frais de position longue en overnight
Long position overnight fee
Aller vers la plateforme | -0.025457% | ||||||||
|
Frais de position courte en overnight
Short position overnight fee
Aller vers la plateforme | 0.003235% | ||||||||
| Durée des frais en overnight | 21:00 (UTC) | ||||||||
| Quantité minimale négociée | 1 | ||||||||
| Devise | USD | ||||||||
| Marge | 20% | ||||||||
| Bourse | United States of America | ||||||||
| Commission sur la négociation | 0% |
*Information provided by Capital.com
Lexicon Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Chiffres clés
| Fermeture précédente* | 2.72 |
| Ouvert* | 2.67 |
| Variation sur 1 an* | 50% |
| Fourchette du jour* | 2.44 - 2.67 |
| Fourchette sur 52 semaines | 1.31-3.79 |
| Volume moyen (10 jours) | 5.05M |
| Volume moyen (3 mois) | 29.81M |
| Capitalisation boursière | 520.35M |
| Ratio C/B | -100.00K |
| Actions en circulation | 244.85M |
| Revenu | 126.00K |
| EPS | -0.63 |
| Dividende (rendement en %) | N/A |
| Bêta | 1.27 |
| Prochaine date de publication des résultats | Jul 31, 2023 |
Toutes les données sont fournies par Refinitiv, à l'exception des données marquées d'un astérisque, qui sont des *données fournies par Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Clôture | Change | Change (%) | Ouverture | High | Low |
|---|---|---|---|---|---|---|
| Jun 2, 2023 | 2.72 | -0.03 | -1.09% | 2.75 | 2.77 | 2.64 |
| Jun 1, 2023 | 2.68 | 0.00 | 0.00% | 2.68 | 2.70 | 2.54 |
| May 31, 2023 | 3.27 | 0.39 | 13.54% | 2.88 | 3.39 | 2.87 |
| May 30, 2023 | 2.86 | -0.52 | -15.38% | 3.38 | 3.43 | 2.65 |
| May 26, 2023 | 3.14 | 0.12 | 3.97% | 3.02 | 3.20 | 2.90 |
| May 25, 2023 | 2.86 | -0.17 | -5.61% | 3.03 | 3.03 | 2.83 |
| May 24, 2023 | 2.98 | -0.04 | -1.32% | 3.02 | 3.02 | 2.94 |
| May 23, 2023 | 3.02 | -0.16 | -5.03% | 3.18 | 3.27 | 3.02 |
| May 22, 2023 | 3.17 | 0.10 | 3.26% | 3.07 | 3.27 | 3.03 |
| May 19, 2023 | 2.97 | 0.04 | 1.37% | 2.93 | 3.00 | 2.86 |
| May 18, 2023 | 2.86 | -0.04 | -1.38% | 2.90 | 2.91 | 2.76 |
| May 17, 2023 | 2.89 | -0.04 | -1.37% | 2.93 | 2.94 | 2.84 |
| May 16, 2023 | 2.90 | -0.03 | -1.02% | 2.93 | 2.95 | 2.81 |
| May 15, 2023 | 2.94 | 0.06 | 2.08% | 2.88 | 3.01 | 2.84 |
| May 12, 2023 | 2.83 | -0.29 | -9.29% | 3.12 | 3.16 | 2.81 |
| May 11, 2023 | 3.10 | 0.06 | 1.97% | 3.04 | 3.17 | 2.98 |
| May 10, 2023 | 3.03 | -0.13 | -4.11% | 3.16 | 3.16 | 2.91 |
| May 9, 2023 | 3.00 | -0.24 | -7.41% | 3.24 | 3.24 | 2.96 |
| May 8, 2023 | 3.23 | -0.27 | -7.71% | 3.50 | 3.53 | 3.20 |
| May 5, 2023 | 3.45 | 0.36 | 11.65% | 3.09 | 3.75 | 3.05 |
Lexicon Events
| Heure (UTC) (UTC) | Pays | Événement |
|---|---|---|
| Monday, July 31, 2023 | ||
| Heure (UTC) (UTC) 10:59 | Pays US
| Événement Q2 2023 Lexicon Pharmaceuticals Inc Earnings Release Q2 2023 Lexicon Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Tuesday, November 7, 2023 | ||
| Heure (UTC) (UTC) 10:59 | Pays US
| Événement Q3 2023 Lexicon Pharmaceuticals Inc Earnings Release Q3 2023 Lexicon Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Revenu total | 0.139 | 0.298 | 23.995 | 322.073 | 63.209 |
| Revenu | 0.139 | 0.298 | 23.995 | 322.073 | 63.209 |
| Coût des recettes, total | 0 | 0 | 1.929 | 3.231 | 2.491 |
| Résultat brut | 0.139 | 0.298 | 22.066 | 318.842 | 60.718 |
| Total des frais d'exploitation | 100.899 | 87.388 | 70.792 | 180.628 | 166.488 |
| Total des frais de vente/Généraux/Admin | 48.083 | 32.342 | 47.23 | 56.835 | 63.754 |
| Recherche et développement | 52.816 | 55.046 | 153.621 | 91.924 | 100.243 |
| Other Operating Expenses, Total | 0 | 0 | |||
| Produits d'exploitation | -100.76 | -87.09 | -46.797 | 141.445 | -103.279 |
| Produits (charges) d'intérêts, nets Hors exploitation | -2.78 | -0.802 | -14.544 | -20.676 | -20.777 |
| Autres, nets | 1.596 | 0.134 | 2.767 | 3.35 | 3.508 |
| Résultat net avant impôts | -101.944 | -87.758 | -58.574 | 124.119 | -120.548 |
| Résultat net après impôts | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Résultat net avant éléments extra | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Résultat net | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Résultat net dilué | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Moyenne pondérée des actions diluées | 165.733 | 145.652 | 110.841 | 116.747 | 105.83 |
| BPA dilué hors éléments extraordinaires | -0.61511 | -0.60252 | -0.52845 | 1.11466 | -1.13907 |
| BPA dilué normalisé | -0.61511 | -0.60252 | -1.71924 | 1.2741 | -1.13907 |
| Total des éléments extraordinaires | 0 | ||||
| Charges (revenus) inhabituelles | 0 | 0 | -131.988 | 28.638 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Revenu total | 0.024 | 0.028 | 0.039 | 0.035 | 0.037 |
| Revenu | 0.024 | 0.028 | 0.039 | 0.035 | 0.037 |
| Coût des recettes, total | |||||
| Résultat brut | |||||
| Total des frais d'exploitation | 31.166 | 30.306 | 23.134 | 24.042 | 23.417 |
| Total des frais de vente/Généraux/Admin | 19.14 | 16.329 | 12.577 | 10.686 | 8.491 |
| Recherche et développement | 12.026 | 13.977 | 10.557 | 13.356 | 14.926 |
| Produits d'exploitation | -31.142 | -30.278 | -23.095 | -24.007 | -23.38 |
| Produits (charges) d'intérêts, nets Hors exploitation | -1.821 | -1.103 | -0.864 | -0.703 | -0.11 |
| Autres, nets | 1.029 | 0.887 | 0.572 | 0.123 | 0.014 |
| Résultat net avant impôts | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
| Résultat net après impôts | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
| Résultat net avant éléments extra | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
| Résultat net | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
| Résultat net dilué | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
| Moyenne pondérée des actions diluées | 189.014 | 188.98 | 174.904 | 149.616 | 149.15 |
| BPA dilué hors éléments extraordinaires | -0.16895 | -0.16136 | -0.13371 | -0.16433 | -0.1574 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA dilué normalisé | -0.16895 | -0.16136 | -0.13371 | -0.16433 | -0.1574 |
| Charges (revenus) inhabituelles | 0 |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 140.866 | 88.921 | 157.719 | 337.754 | 173.324 |
| Espèces et placements à court terme | 138.357 | 86.743 | 152.275 | 271.659 | 160.052 |
| Trésorerie et équivalents | 46.345 | 64.065 | 126.263 | 36.112 | 80.386 |
| Investissements à court terme | 92.012 | 22.678 | 26.012 | 235.547 | 79.666 |
| Total des créances, nettes | 0.028 | 0.014 | 0.395 | 56.532 | 5.924 |
| Accounts Receivable - Trade, Net | 0.028 | 0.014 | 0.395 | 56.532 | 5.924 |
| Prepaid Expenses | 2.481 | 2.164 | 5.049 | 5.32 | 2.668 |
| Total Assets | 194.299 | 136.909 | 203.788 | 417.715 | 284.136 |
| Property/Plant/Equipment, Total - Net | 4.371 | 3.476 | 1.495 | 15.747 | 15.865 |
| Property/Plant/Equipment, Total - Gross | 8.355 | 8.329 | 7.31 | 77.488 | 75.871 |
| Accumulated Depreciation, Total | -3.984 | -4.853 | -5.815 | -61.741 | -60.006 |
| Goodwill, Net | 44.543 | 44.543 | 44.543 | 44.543 | 44.543 |
| Intangibles, Net | 0 | 19.716 | 50.119 | ||
| Other Long Term Assets, Total | 4.519 | -0.031 | 0.031 | -0.045 | 0.285 |
| Total Current Liabilities | 23.172 | 22.124 | 46.806 | 65.341 | 36.751 |
| Accounts Payable | 10.395 | 9.152 | 5.469 | 12.178 | 17.759 |
| Accrued Expenses | 12.373 | 10.469 | 29.691 | 42.151 | 14.482 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 11.646 | 11.012 | 1.115 | |
| Other Current Liabilities, Total | 0.404 | 2.503 | 0 | 3.395 | |
| Total Liabilities | 77.175 | 23.314 | 47.417 | 300.614 | 310.541 |
| Total Long Term Debt | 48.579 | 0 | 0 | 234.171 | 243.887 |
| Long Term Debt | 48.579 | 0 | 234.171 | 243.887 | |
| Deferred Income Tax | 0 | 6.014 | |||
| Other Liabilities, Total | 5.424 | 1.19 | 0.611 | 1.102 | 23.889 |
| Total Equity | 117.124 | 113.595 | 156.371 | 117.101 | -26.405 |
| Common Stock | 0.189 | 0.15 | 0.142 | 0.106 | 0.106 |
| Additional Paid-In Capital | 1709.14 | 1608.75 | 1561.1 | 1462.17 | 1447.95 |
| Retained Earnings (Accumulated Deficit) | -1589.72 | -1487.78 | -1400.02 | -1341.44 | -1471.58 |
| Treasury Stock - Common | -2.061 | -7.518 | -4.843 | -3.817 | -2.876 |
| Other Equity, Total | -0.428 | -0.01 | -0.006 | 0.084 | -0.012 |
| Total Liabilities & Shareholders’ Equity | 194.299 | 136.909 | 203.788 | 417.715 | 284.136 |
| Total Common Shares Outstanding | 188.726 | 148.917 | 141.496 | 106.272 | 105.926 |
| Total Inventory | 0 | 4.243 | 4.68 | ||
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 109.546 | 140.866 | 139.063 | 64.898 | 88.431 |
| Espèces et placements à court terme | 105.937 | 138.357 | 136.203 | 61.968 | 86.502 |
| Trésorerie et équivalents | 26.001 | 46.345 | 18.834 | 21.45 | 59.52 |
| Investissements à court terme | 79.936 | 92.012 | 117.369 | 40.518 | 26.982 |
| Total des créances, nettes | 0.261 | 0.028 | 0.039 | 0.034 | 0.037 |
| Accounts Receivable - Trade, Net | 0.261 | 0.028 | 0.039 | 0.034 | 0.037 |
| Prepaid Expenses | 3.348 | 2.481 | 2.821 | 2.896 | 1.892 |
| Total Assets | 162.716 | 194.299 | 191.685 | 112.325 | 136.178 |
| Property/Plant/Equipment, Total - Net | 8.627 | 4.371 | 8.032 | 2.835 | 3.242 |
| Property/Plant/Equipment, Total - Gross | 6.303 | 8.355 | 6.109 | 6.105 | 6.104 |
| Accumulated Depreciation, Total | -4.096 | -3.984 | -5.177 | -5.07 | -4.962 |
| Goodwill, Net | 44.543 | 44.543 | 44.543 | 44.543 | 44.543 |
| Other Long Term Assets, Total | 4.519 | 0.047 | 0.049 | -0.038 | |
| Total Current Liabilities | 20.371 | 23.172 | 18.445 | 16.862 | 18.905 |
| Accounts Payable | 10.311 | 10.395 | 9.427 | 7.347 | 9.321 |
| Accrued Expenses | 9.576 | 12.373 | 8.299 | 9.038 | 8.864 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | |||||
| Total Liabilities | 74.67 | 77.175 | 47.667 | 41.495 | 43.48 |
| Total Long Term Debt | 48.845 | 48.579 | 23.784 | 23.631 | 23.477 |
| Other Liabilities, Total | 5.454 | 5.424 | 5.438 | 1.002 | 1.098 |
| Total Equity | 88.046 | 117.124 | 144.018 | 70.83 | 92.698 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.19 | 0.189 | 0.189 | 0.15 | 0.15 |
| Additional Paid-In Capital | 1712.56 | 1709.14 | 1705.61 | 1608.73 | 1605.9 |
| Retained Earnings (Accumulated Deficit) | -1621.65 | -1589.72 | -1559.23 | -1535.84 | -1511.25 |
| Treasury Stock - Common | -2.885 | -2.061 | -2.061 | -2.061 | -2.061 |
| Other Equity, Total | -0.163 | -0.428 | -0.491 | -0.15 | -0.037 |
| Total Liabilities & Shareholders’ Equity | 162.716 | 194.299 | 191.685 | 112.325 | 136.178 |
| Total Common Shares Outstanding | 189.562 | 188.726 | 188.726 | 149.626 | 149.594 |
| Other Current Liabilities, Total | 0.484 | 0.404 | 0.719 | 0.477 | 0.72 |
| Long Term Debt | 48.845 | 48.579 | 23.784 | 23.631 | 23.477 |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Revenu net/Ligne de départ | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Liquidités provenant des activités d'exploitation | -88.851 | -87.017 | -142.969 | 113.807 | -148.607 |
| Liquidités provenant des activités d'exploitation | 0.427 | 0.292 | 2.934 | 3.654 | 3.683 |
| Deferred Taxes | 0 | 0 | -6.014 | 0 | |
| Éléments non monétaires | 12.264 | 10.68 | -118.408 | 44.321 | 13.032 |
| Intérêts payés en espèces | 2.289 | 0.799 | 17.353 | 19.211 | 16.465 |
| Variation du fonds de roulement | 0.402 | -10.231 | 31.079 | -58.287 | -44.774 |
| Flux de trésorerie liés aux activités d'investissement | -71.078 | 2.11 | 380.756 | -155.855 | 169.576 |
| Dépenses d'investissement | -1.326 | -1.221 | -0.087 | -0.07 | -0.095 |
| Autres éléments de flux de trésorerie d'investissement, total | -69.752 | 3.331 | 380.843 | -155.785 | 169.671 |
| Flux de trésorerie provenant des activités de financement | 142.209 | 22.709 | -147.636 | -2.226 | -2.244 |
| Émission (remboursement) d'actions, nette | 93.341 | 34.409 | 68.944 | -0.941 | -0.24 |
| Émission (remboursement) de la dette, nette | 48.868 | -11.7 | -216.58 | -1.285 | -2.004 |
| Variation nette de la trésorerie | -17.72 | -62.198 | 90.151 | -44.274 | 18.725 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -31.934 | -101.944 | -71.45 | -48.063 | -23.476 |
| Cash From Operating Activities | -31.613 | -88.851 | -67.282 | -47.843 | -23.421 |
| Cash From Operating Activities | 0.112 | 0.427 | 0.324 | 0.216 | 0.109 |
| Non-Cash Items | 3.68 | 12.264 | 8.648 | 5.783 | 2.797 |
| Cash Interest Paid | 1.556 | 2.289 | 1.281 | 0.634 | 0.085 |
| Changes in Working Capital | -3.471 | 0.402 | -4.804 | -5.779 | -2.851 |
| Cash From Investing Activities | 12.093 | -71.078 | -95.252 | -18.056 | -4.408 |
| Capital Expenditures | -0.248 | -1.326 | -0.08 | -0.076 | -0.076 |
| Other Investing Cash Flow Items, Total | 12.341 | -69.752 | -95.172 | -17.98 | -4.332 |
| Cash From Financing Activities | -0.824 | 142.209 | 117.303 | 23.284 | 23.284 |
| Issuance (Retirement) of Stock, Net | -0.824 | 93.341 | 93.404 | -0.864 | -0.864 |
| Issuance (Retirement) of Debt, Net | 0 | 48.868 | 23.899 | 24.148 | 24.148 |
| Net Change in Cash | -20.344 | -17.72 | -45.231 | -42.615 | -4.545 |
| Deferred Taxes |
| Nom de l'investisseur | Catégorie de l'investisseur | Pourcentage de l'encours | Actions détenues | Changement d'actions | Date d'avoirs | Taux du chiffre d'affaires |
|---|---|---|---|---|---|---|
| Artal International S.C.A. | Investment Advisor | 45.506 | 86262020 | 0 | 2023-03-31 | LOW |
| BVF Partners L.P. | Hedge Fund | 8.5192 | 16149179 | 0 | 2023-03-31 | LOW |
| Ulys, L.L.C. | Investment Advisor | 2.7979 | 5303814 | 0 | 2022-08-01 | |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.792 | 5292626 | 43032 | 2023-03-31 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 2.7644 | 5240247 | -11438 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.6709 | 5062976 | -201281 | 2023-03-31 | LOW |
| Invus Public Equities Advisors, LLC | Investment Advisor | 1.8549 | 3516214 | 0 | 2023-03-31 | LOW |
| JP Morgan Asset Management | Investment Advisor | 1.6081 | 3048374 | 56229 | 2023-03-31 | LOW |
| D. E. Shaw & Co., L.P. | Hedge Fund | 1.5515 | 2940997 | -136976 | 2023-03-31 | LOW |
| New Enterprise Associates (NEA) | Venture Capital | 1.2567 | 2382286 | 0 | 2023-03-31 | LOW |
| Pinnacle Associates Ltd. | Investment Advisor/Hedge Fund | 1.0235 | 1940224 | 7447 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.9102 | 1725409 | 117468 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.8251 | 1564098 | 47623 | 2023-03-31 | LOW |
| Coats Lonnel | Individual Investor | 0.3927 | 744359 | 158356 | 2023-02-28 | LOW |
| Fisher Investments | Investment Advisor/Hedge Fund | 0.38 | 720243 | 0 | 2023-03-31 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.3794 | 719182 | 306384 | 2023-03-31 | LOW |
| Charles Schwab Investment Management, Inc. | Investment Advisor | 0.3633 | 688611 | -7329 | 2023-03-31 | LOW |
| Parkman Healthcare Partners LLC | Hedge Fund | 0.3563 | 675328 | 254126 | 2023-03-31 | HIGH |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.3561 | 675018 | -19915 | 2023-03-31 | LOW |
| Asset Management One Co., Ltd. | Investment Advisor/Hedge Fund | 0.3194 | 605528 | 605528 | 2022-08-31 | LOW |
Pourquoi choisir capital.com? Nos chiffres parlent d'eux-mêmes.
Capital.com Group535K+
Tradeurs
87K+
Clients actifs par mois
$113M+
Volume d'investissement par mois
$64M+
Retrait par mois
Trading calculator
Calculez votre P&L hypothétique si vous aviez ouvert une transaction CFD à une certaine date (sélectionnez une date) et l'aviez fermée à une autre date (sélectionnez une date).
Trade commission
0
- 1:1
Effet de levier
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Ouverture
Clôture
Short Long
Lexicon Company profile
À propos de Lexicon
Lexicon Pharmaceuticals, Inc. est une société biopharmaceutique. La société se concentre sur la découverte, le développement et la commercialisation de produits pharmaceutiques pour le traitement de maladies humaines. Son pipeline comprend Sotagliflozin, LX9211, et LX2761. La sotagliflozine est une petite molécule administrée par voie orale qui est en cours de développement pour le traitement de l'insuffisance cardiaque et du diabète de type I, et du diabète de type II, de l'insuffisance cardiaque et de la maladie rénale chronique. Le LX9211 est une petite molécule administrée par voie orale qui est développée pour le traitement de la douleur neuropathique. La société mène un essai clinique de phase II du LX9211 sur la douleur neuropathique périphérique diabétique et un second essai clinique de phase II du LX9211 sur la névralgie post-herpétique. Le LX2761 est une petite molécule administrée par voie orale, conçue pour inhiber le cotransporteur 1 du sodium-glucose (SGLT1) localement dans le tractus gastro-intestinal sans inhiber le cotransporteur 2 du sodium-glucose (SGLT2) dans le rein.
| Industry: | Bio Therapeutic Drugs |
8800 Technology Forest Place
8800 Technology Forest Place
77381
Compte de résultat
- Annual
- Quarterly
Les gens regardent aussi
Êtes-vous toujours à la recherche d'un broker de confiance?
Rejoignez les plus de 535 000 traders du monde entier qui ont choisi de trader avec Capital.com